Table 1.
Baseline patient characteristics of the study.
| Patient characteristics | No. of patients (%) | P | ||
|---|---|---|---|---|
| Erlotinib (n = 74) | Gefitinib (n = 83) | All patients (n = 157) | ||
| Age, years | 0.934 | |||
| Median (range) | 57 (27–77) | 56 (32–82) | 56 (27–82) | |
| <65 | 61 (82) | 68 (82) | 129 (82) | |
| ≥ 65 | 13 (18) | 15 (18) | 28 (18) | |
| Sex | 0.256 | |||
| Male | 37 (50) | 34 (41) | 71 (45) | |
| Female | 37 (50) | 49 (59) | 86 (55) | |
| ECOG PS | 0.422 | |||
| 0–1 | 70 (95) | 81 (98) | 151 (96) | |
| 2 | 4 (5) | 2 (2) | 6 (4) | |
| Histology | 0.851 | |||
| Adeno | 69 (93) | 78 (94) | 147 (94) | |
| Non-adenoa | 5 (7) | 5 (6) | 10 (6) | |
| Disease stage | 0.602 | |||
| IV | 72 (97) | 82 (99) | 154 (98) | |
| IIIB | 2 (3) | 1 (1) | 3 (2) | |
| Line of EGFR-TKI | 0.774 | |||
| 1st line | 55 (74) | 60 (72) | 115 (73) | |
| 2nd line or beyondb | 19 (26) | 23 (28) | 42 (27) | |
| Prior Surgery | 0.828 | |||
| Yes | 15 (20) | 18 (22) | 33 (21) | |
| No | 59 (80) | 65 (78) | 124 (79) | |
| Prior Radiotherapy | 0.736 | |||
| Yes | 5 (7) | 4 (5) | 9 (6) | |
| No | 69 (93) | 79 (95) | 148 (94) | |
| Prior Chemotherapyc | 0.774 | |||
| Yes | 19 (26) | 23 (28) | 42 (27) | |
| No | 55 (74) | 60 (72) | 115 (73) | |
| Baseline CNS metastasis | 0.694 | |||
| Yes | 29 (39) | 30 (36) | 59 (38) | |
| No | 45 (61) | 53 (64) | 98 (62) | |
| Baseline Liver metastasis | 0.316 | |||
| Yes | 13 (18) | 20 (24) | 33 (21) | |
| No | 61 (82) | 63 (76) | 124 (79) | |
| EGFR mutation | 0.593 | |||
| Exon19 deletion | 46 (62) | 45 (54) | 91 (58) | |
| L858R mutation | 27 (36) | 36 (43) | 63 (40) | |
| Othersd | 1 (1) | 2 (2) | 3 (2) | |
ECOG PS, Eastern Cooperative Oncology Group performance status; Adeno, adenocarcinoma; EGFR TKI, epidermal growth factor receptors tyrosine kinase inhibitors; EGFR, epidermal growth factor receptors.
a
non-adenocarcinoma included squamous-cell carcinoma (n = 6), large-cell carcinoma (n = 3), and bronchoalveolar carcinoma (n = 1).
b
included four patients in the third-line settings.
c
patients who had received chemotherapy were all treated with at least one cycle of platinum-based doublet chemotherapy.
d
included two patients with L861Q mutations, one patient with G719A mutation.